Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

PLoS Medicine

Volumn 13, Issue 10, 2016, Pages

  Todd, John A ^a,i   Evangelou, Marina ^b   Cutler, Antony J ^a,i   Pekalski, Marcin L ^a,i   Walker, Neil M ^a   Stevens, Helen E ^a   Porter, Linsey ^a   Smyth, Deborah J ^a   Rainbow, Daniel B ^a,i   Ferreira, Ricardo C ^a,i   Esposito, Laura ^a   Hunter, Kara M D ^a   Loudon, Kevin ^a   Irons, Kathryn ^c   Yang, Jennie H ^d   Bell, Charles J M ^a   Schuilenburg, Helen ^a   Heywood, James ^a   Challis, Ben ^e   Neupane, Sankalpa ^e   Clarke, Pamela ^a   Coleman, Gillian ^a   Dawson, Sarah ^a   Goymer, Donna ^a   Anselmiova, Katerina ^a   Kennet, Jane ^a   Brown, Judy ^a   Caddy, Sarah L ^f   Lu, Jia ^f   Greatorex, Jane ^g   Goodfellow, Ian ^f   Wallace, Chris ^a,h   Tree, Tim I ^d   Evans, Mark ^e   Mander, Adrian P ^h   Bond, Simon ^c,h   Wicker, Linda S ^a,i   Waldron Lynch, Frank ^a,j   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; INTERLEUKIN 2; ALDESLEUKIN; AUTACOID; BIOLOGICAL MARKER; CHEMOKINE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLOOD VOLUME; CELL PROLIFERATION; CLINICAL ARTICLE; ERYTHEMA; EVALUATION AND FOLLOW UP; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMMUNOPHENOTYPING; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NOSE OBSTRUCTION; PHLEBOTOMY; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; EOSINOPHIL; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; BIOMARKERS; CHEMOKINES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84994226769     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002139     Document Type: Article

References (61)

1. Atkinson MA, Eisenbarth GS, Michels AW, Type 1 diabetes. Lancet. 2014;383:69–82. doi: 10.1016/S0140-6736(13)60591-723890997
2. McKnight JA, Wild SH, Lamb MJ, Cooper MN, Jones TW, Davis EA, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32:1036–1050. doi: 10.1111/dme.1267625510978
3. Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971–978. doi: 10.2337/dc15-007825998289
4. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56:391–400. doi: 10.1007/s00125-012-2753-423086558
5. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361:2143–2152. doi: 10.1056/NEJMoa090445219940299
6. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–2608. doi: 10.1056/NEJMoa04398015972866
7. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125:3285–3296. doi: 10.1172/JCI8172226193635
8. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–419. doi: 10.1016/S0140-6736(11)60886-621719096
9. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–860. doi: 10.1038/ng.331426121088
10. Cho JH, Feldman M, Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med. 2015;21:730–738. doi: 10.1038/nm.389726121193
11. Todd JA, Aitman TJ, Cornall RJ, Ghosh S, Hall JR, Hearne CM, et al. Genetic analysis of autoimmune type 1 diabetes mellitus in mice. Nature. 1991;351:542–547. doi: 10.1038/351542a01675432
12. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet. 2007;39:329–337. doi: 10.1038/ng195817277778
13. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet. 2005;76:773–779. doi: 10.1086/42984315776395
14. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007;39:1074–1082. doi: 10.1038/ng210217676041
15. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857–864. doi: 10.1038/ng206817554260
16. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009;41:1011–1015. doi: 10.1038/ng.43419701192
17. Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, Pekalski M, et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol. 2012;188:4644–4653. doi: 10.4049/jimmunol.110027222461703
18. Thompson WS, Pekalski ML, Simons HZ, Smyth DJ, Castro-Dopico X, Guo H, et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol. 2014;177:571–585. doi: 10.1111/cei.1236224773525
19. Boyman O, Sprent J, The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180–190. doi: 10.1038/nri315622343569
20. Liao W, Lin JX, Leonard WJ, Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13–25. doi: 10.1016/j.immuni.2013.01.00423352221
21. Liston A, Gray DH, Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14:154–165. doi: 10.1038/nri360524481337
22. Liu Z, Gerner MY, Van Panhuys N, Levine AG, Rudensky AY, Germain RN, Immune homeostasis enforced by co-localized effector and regulatory T cells. Nature. 2015;528:225–230. doi: 10.1038/nature1616926605524
23. Setoguchi R, Hori S, Takahashi T, Sakaguchi S, Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723–735. doi: 10.1084/jem.2004198215753206
24. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116. 10561265
25. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunothérapie. N Engl J Med. 1998;338:1272–1278. doi: 10.1056/NEJM1998043033818059562581
26. Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest. 2014;124:99–110. doi: 10.1172/JCI4626624292706
27. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–697. doi: 10.1016/j.immuni.2008.03.01618468463
28. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207:1871–1878. doi: 10.1084/jem.2010020920679400
29. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–2066. doi: 10.1056/NEJMoa110818822129252
30. Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft vs. host disease. Blood. 2016;128:130–137. doi: 10.1182/blood-2016-02-70285227073224
31. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365:2067–2077. doi: 10.1056/NEJMoa110514322129253
32. Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015;74:791–792. doi: 10.1136/annrheumdis-2014-20650625609413
33. Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150:748–751. doi: 10.1001/jamadermatol.2014.50424872229
34. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012. doi: 10.2337/db12-0049
35. Long SA, Buckner JH, Greenbaum CJ, IL-2 therapy in type 1 diabetes: “Trials” and tribulations. Clin Immunol. 2013;149:324–331. doi: 10.1016/j.clim.2013.02.00523499139
36. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:295–305. doi: 10.1016/S2213-8587(13)70113-X24622415
37. Low-dose rhIL-2 in patients with recently-diagnosed type 1 diabetes (DIABIL-2). ClinicalTrials.gov. 2016 Feb 15 [cited 26 Jul 2016]. Available: https://clinicaltrials.gov/ct2/show/NCT02411253.
38. Staeva-Vieira T, Peakman M, von Herrath M, Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol. 2007;148:17–31. doi: 10.1111/j.1365-2249.2007.03328.x17349010
39. Lernmark A, Larsson HE, Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol. 2013;9:92–103. doi: 10.1038/nrendo.2012.23723296174
40. Kenefeck R, Wang CJ, Kapadi T, Wardzinski L, Attridge K, Clough LE, et al. Follicular helper T cell signature in type 1 diabetes. J Clin Invest. 2015;125:292–303. doi: 10.1172/JCI7623825485678
41. Ferreira RC, Simons HZ, Thompson WS, Cutler AJ, Dopico XC, Smyth DJ, et al. IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia. 2015;58:781–790. doi: 10.1007/s00125-015-3509-825652388
42. Waldron-Lynch F, Kareclas P, Irons K, Walker NM, Mander A, Wicker LS, et al. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open. 2014;4:e005559. doi: 10.1136/bmjopen-2014-00555924898091
43. Yang JH, Cutler AJ, Ferreira RC, Reading JL, Cooper NJ, Wallace C, et al. Natural variation in interleukin-2 sensitivity influences regulatory T-cell frequency and function in individuals with long-standing type 1 diabetes. Diabetes. 2015;64:3891–3902. doi: 10.2337/db15-051626224887
44. Rainbow DB, Yang X, Burren O, Pekalski ML, Smyth DJ, Klarqvist MD, et al. Epigenetic analysis of regulatory T cells using multiplex bisulfite sequencing. Eur J Immunol. 2015;45:3200–3203. doi: 10.1002/eji.20154564626420295
45. Glezer EN, Stengelin M, Aghvanyan A, Nikolenko GN, Roy D, Higgins M, et al. Cytokine immunoassays with sub-fg/ml detection limits. AAPS 2014 National Biotechnology Conference; 19–21 May 2014; San Diego, CA, US.
46. Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, et al. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun. 2015;56:66–80. doi: 10.1016/j.jaut.2014.10.00225457307
47. Downes K, Marcovecchio ML, Clarke P, Cooper JD, Ferreira RC, Howson JM, et al. Plasma concentrations of soluble IL-2 receptor α (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients. Diabetologia. 2014;57:366–372. doi: 10.1007/s00125-013-3113-824264051
48. Heywood J, Evangelou M, Goymer D, Kennet J, Anselmiova K, Guy C, et al. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). Trials. 2015;16:86. doi: 10.1186/s13063-015-0583-725881192
49. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990;50:2009–2017. 2317789
50. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ, Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012;119:4430–4440. doi: 10.1182/blood-2011-11-39232422438251
51. The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. 8366922
52. Kuhtreiber WM, Washer SL, Hsu E, Zhao M, Reinhold P, Burger D, et al. Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabet Med. 2015;32:1346–1353. doi: 10.1111/dme.1285026172028
53. Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22:1388–1395. doi: 10.1038/mt.2014.5024686272
54. Electronic Medicines Compendium. Proleukin. 2015 Jan 20 [cited 17 Mar 2016]. Available: http://www.medicines.org.uk/emc/medicine/19322.
55. Itano AA, Sims MJ, Siu G, Mechanistic medicine: novel strategies for clinical trials. Autoimmunity. 2010;43:560–571. doi: 10.3109/0891693100367478220429849
56. Truman LA, Pekalski ML, Kareclas P, Evangelou M, Walker NM, Howlett J, et al. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. BMJ Open. 2015;5:e009799. doi: 10.1136/bmjopen-2015-00979926646829
57. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103:5941–5946. doi: 10.1073/pnas.060133510316585503
58. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62:3766–3774. doi: 10.2337/db13-034523835333
59. Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med. 2012;4:118ra12. doi: 10.1126/scitranslmed.300340122277969
60. Chatenoud L, Primo J, Bach JF, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol. 1997;158:2947–2954. 9058834
61. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA, Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003;111:409–418. doi: 10.1172/JCI1609012569167